Evidence map›Paper›PMID 39610204›Full record

Trial reportClinical and translational science2024

Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification.

Jiajia Yuan, Lin Shen, Tian Shu Liu, HuiTing Xu, Jianwei Yang, Jia Wei, Haiping Jiang, Yanhong Deng, Hongming Pan, Yusheng Wang and 10 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and translational science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jiajia YuanPeking University Cancer Hospital and Institute, Beijing, China.
Lin ShenPeking University Cancer Hospital and Institute, Beijing, China.
Tian Shu LiuZhongshan Hospital Affiliated to Fudan University, Shanghai, China.
HuiTing XuHubei Cancer Hospital, Wuhan, China.
Jianwei YangFujian Provincial Cancer Hospital, Fuzhou, China.
Jia WeiNanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Haiping JiangThe First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Yanhong DengThe Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Hongming PanSir Run Run Shaw Hospital affiliated with Zhejiang University School of Medicine, Hanzhou, China.
Yusheng WangShanxi Cancer Hospital, Taiyuan, China.
Xiaotian ZhangPeking University Cancer Hospital and Institute, Beijing, China.
Zhi PengPeking University Cancer Hospital and Institute, Beijing, China.
Changsong QiPeking University Cancer Hospital and Institute, Beijing, China.
Lingli ZhangShanghai LianBio Development Co., Ltd, Shanghai, China.ORCID 0009-0003-4934-8374
Peiwen HsuShanghai LianBio Development Co., Ltd, Shanghai, China.
Lin SongShanghai LianBio Development Co., Ltd, Shanghai, China.ORCID 0009-0007-9498-1805
Lei MuShanghai LianBio Development Co., Ltd, Shanghai, China.
Qiao SunShanghai LianBio Development Co., Ltd, Shanghai, China.ORCID 0009-0000-1816-5207
Jifang GongPeking University Cancer Hospital and Institute, Beijing, China.
Cheng LyuShanghai LianBio Development Co., Ltd, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infigratinib, an FGFR1-3 selective oral tyrosine kinase inhibitor, has shown clinical activity in cancers with FGFR alterations. The pharmacokinetics (PK) of infigratinib and its major metabolites have been characterized in global populations. This study examined the PK profile of infigratinib and its metabolites in Chinese patients. In this phase II, open-label, single-arm study in China, patients with advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) harboring FGFR2 gene amplification received 125 mg infigratinib orally once daily in a "3 weeks on, 1 week off" schedule for 28-day cycles. Plasma PK parameters were calculated with a non-compartmental model. Data were available from 21 patients (19 GC and two GEJ). After a single dose, peak infigratinib plasma concentration was reached at a median time of 3.1 h, with geometric mean C

Indexed as

Gene AmplificationReceptor, Fibroblast Growth Factor, Type 2Stomach NeoplasmsAdministration, OralAdultAgedAntineoplastic AgentsChinaEast Asian PeopleFemaleHumansMaleMiddle AgedPhenylurea CompoundsProtein Kinase InhibitorsPyrimidinesAntineoplastic AgentsFGFR2 protein, humaninfigratinibPhenylurea CompoundsProtein Kinase InhibitorsPyrimidinesReceptor, Fibroblast Growth Factor, Type 2

Identifiers

PMID39610204
PMCPMC11604989

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.